BCL3 and colorectal carcinoma: In light of the well characterized increases in BCL3 expression in CRC patient tumours [88, 89] this study provides a rationale for a role of BCL3 in driving resistance to DNA damaging agents in CRC and for the inclusion of BCL3 inhibitors as an adjunct to existing standard of care for CRC patients in the future.